Creating new methods to build carbon-carbon bonds for drug development
Exploiting Interfacial Design for the Electrocatalytic Construction of C-C bonds
['FUNDING_OTHER'] · UNIVERSITY OF CHICAGO · NIH-11082388
This study is exploring a new way to create important ingredients for medicines using electricity, which could make it easier and faster to produce complex drugs that help people.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CHICAGO (nih funded) |
| Locations | 1 site (CHICAGO, UNITED STATES) |
| Trial ID | NIH-11082388 on ClinicalTrials.gov |
What this research studies
This research aims to innovate drug discovery by developing a new synthetic platform that utilizes electricity to drive organic transformations. It focuses on coupling various organic halides with aldehydes and ketones to create carbon-carbon bonds with high selectivity. By optimizing the interactions between the electrode material and the electrophiles, the research seeks to produce new chiral alcohols and derivatives that are important in pharmaceuticals. This approach could simplify the synthesis of complex drugs, making them more accessible and efficient to produce.
Who could benefit from this research
Good fit: Ideal candidates for benefiting from this research include individuals requiring new or improved medications for various diseases.
Not a fit: Patients who are not seeking new drug therapies or those with conditions that do not require pharmaceutical intervention may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more efficient and cost-effective methods for producing essential pharmaceuticals.
How similar studies have performed: Other research has shown promise in using electrocatalytic methods for organic synthesis, indicating potential for success in this novel approach.
Where this research is happening
CHICAGO, UNITED STATES
- UNIVERSITY OF CHICAGO — CHICAGO, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: WUTTIG, ANNA — UNIVERSITY OF CHICAGO
- Study coordinator: WUTTIG, ANNA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.